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Short Communication
Further Characterization of Three Yersinia enterocolitica
Strains with a Nalidixic Acid–Resistant Phenotype
Isolated from Humans with Diarrhea
Niall Drummond,1 Roger Stephan,2 Pippa Haughton,1 Brenda P. Murphy,1 and Se´amus Fanning1
Abstract
Antimicrobial-resistant bacteria pose a threat to public health. Three Yersinia enterocolitica strains cultured from
patients presenting with diarrhea and resistant to nalidixic acid were studied. Target gene mutations in gyrA
alone were identified as part of the genetic basis for this phenotype. Efflux activity was also noted, since the
presence of the efflux pump inhibitor, phenylalanine-arginine-b-naphthylamide, increased susceptibility to na-
lidixic acid.
Introduction
Yersiniosis, a foodborne disease, is characterized bysymptoms including diarrhea, fever, abdominal pain,
and vomiting (Drummond et al., 2012). Fluoroquinolones (FQ)
are used for the treatment of this infection, particularly in
immunocompromised individuals (Capilla et al., 2004). In
Gram-negative bacteria, three mechanisms of FQ resistance
have been described including target gene mutation(s);
reduction in drug accumulation; and plasmid-mediated qui-
nolone resistance (PMQR). DNA gyrase and DNA topoi-
somerase IV are tetrameric enzymes and are the targets for
quinolone drugs. Resistance has been attributed to chromo-
somal mutations in the corresponding subunit-encoding
genes (gyrA, gyrB for DNA gyrase and/or parC and parE for
topoisomerase IV) (Ruiz, 2003).Within these loci, the quinolone-
resistance-determining region (QRDR) is a mutational hot
spot (Fa`brega et al., 2010). Several mutations have already
been identified in gyrA in Yersinia enterocolitica, the most
common of which lead to amino acid substitutions at Ser-83
and Asp-87, conferring resistance to nalidixic acid (Sa´nchez-
Ce´spedes et al., 2003; Capilla et al, 2004; Sihvonen et al., 2011).
Compared to other members of the Enterobacteriaceae,
quinolone resistance in Y. enterocolitica is not commonly
encountered. In this study, chromosomal- and plasmid-
mediated resistance mechanisms were investigated in three
nalidixic acid–resistant Y. enterocolitica recovered from
humans in Switzerland. The data presented extend our
understanding of this resistance type in these foodborne
pathogens.
Materials and Methods
Bacterial strains and culture conditions
Three Y. enterocolitica strains (Table 1), isolated between
2006 and 2010 from humans in Switzerland, along with
Y. enterocolitica 8081 and a reference-strain Y. enterocolitica
ATCC9610, were included in this study. All bacteria were
subcultured and maintained as described previously (Mur-
phy et al., 2010).
Antimicrobial susceptibility testing
Susceptibility testing was performed by disc diffusion,
using a panel of antimicrobial agents including the following:
amoxicillin-clavulanic acid 30 (10 + 20) lg, ampicillin 10 lg,
cefoxitin 30lg, ceftazidime 30 lg, cefpodoxime 10lg, cefur-
oxime 30 lg, cephalothin 30lg, ciprofloxacin 5lg, gentamicin
10 lg, kanamycin 30 lg, nalidixic acid 30lg, streptomycin
10 lg, tetracycline 30lg, and trimethoprim/sulfamethox-
azole 25 (1.25 + 23.75) lg.
Susceptibility or resistance was interpreted according to the
Clinical and Laboratory Standards Institute (CLSI, 2008)
guidelines and minimum inhibitory concentrations (MIC) for
nalidixic acid and ciprofloxacin were determined by E-test on
Mueller-Hinton agar following themanufacturer’s instructions
(AB-Biodisk, Solna, Sweden). E-tests were also performed in
the presence of the efflux pump inhibitor phenylalanine-
arginine-b-naphthylamide, which was added to Mueller-
Hinton agar plates at a concentration of 20mg/L. Escherichia
coli ATCC25922 was used for quality-control purposes.
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Detection of virulence markers and the
Y. enterocolitica–specific 16S rRNA gene
by polymerase chain reaction (PCR)
Template DNAwas prepared and three specific primer sets
(Eurofins MWG Operon, Ebersberg, Germany) were used to
amplify ail (Falca˜o et al., 2004), pYad (Lantz et al., 1998), and
the Y. enterocolitica–specific chromosomal 16S rRNA genes
(Murphy et al., 2010). Amplification reactions were performed
as described previously (Murphy et al., 2010).
PCR amplification and DNA sequence analysis
of QRDR and PMQR
QRDR containing regions of the target genes were amplified
byPCR. Primer sequences andPCR conditions applied in 50-lL
final reaction mixtures are shown in Supplementary Table S1
(Supplementary Data are available online at www.liebertpub
.com/fpd). DNA sequences were analyzed for mutations
using DNAStar software (Madison, WI), BLAST (http://
blast.ncbi.nlm.nih.gov/), and ClustalW (http://www.ebi
.ac.uk/clustalw). Similarly, PMQR primers and amplification
conditions are shown in Supplementary Table S2. All ampli-
cons produced were separated by electrophoresis in a 1.5%
agarose gel (SeaKem LE Agarose, Lonza Wokingham, Ltd.,
UK) containing 0.1 lg/mL EB (Sigma, Ireland) in 1 X Tris–
boric acid–EDTA buffer (pH 8) (Sigma).
Results and Discussion
The three Y. enterocolitica strains were isolated from hu-
mans between 2006 and 2010, in Switzerland. Two of the
isolates were bio/serotypes 4:O3 (506-06 and 10-2307) and are
classified as pathogenic. The remaining isolate was of biotype
1A (871-07). Isolates 506-06 and 10-2307 harbored the large
pVYe plasmid of 67-kb (data not shown) andwere positive for
the ail and pYad markers, features associated with pathogenic
Y. enterocolitica bio/serotypes (Lantz et al., 1998; Falca˜o et al.,
2004; Thisted Lambertz et al., 2006). Isolate 871-07 did not
contain this plasmid, consistent with the lack of ail and pYad
markers, and the 1A biotype.
All three clinical isolates were resistant to nalidixic acid by
disk diffusion with resistance profiles including 506-06:
AmpKfNaSSxt; 871-07: AmcAmpKfNa; 10-2307: AmpKfNa.
Two of the three clinical isolates (506-06 and 871-7, Table 1)
were resistant to nalidixic acid with MIC> 256mg/L. All
three clinical isolates were susceptible to ciprofloxacin and
none contained PMQR markers (data not shown).
The amino acid substitutions associated with nalidixic acid
resistance are summarized in Table 2. A mutation in gyrA was
identified in isolate 871-07 consistent with the substitution of
Ser-83-Ile, and an Asp-87-Tyr substitution was identified in
isolate 506-06, similar to the change in Y. enterocolitica 8081.
Mutations in these loci contributed to a nalidixic acid–resistant
phenotype, as determined by E-test (Table 1). Furthermore, no
mutations in gyrB, parC, or parE were detected.
Measurement of MICs to nalidixic acid and ciprofloxacin
in the presence of phenylalanine-arginine-b-naphthylamide
contributed to an increase in susceptibility with the exception
of the reference strain, in respect of ciprofloxacin (Table 1).
These findings suggest that efflux activity in this bacterium
contributes to quinolone/FQ resistance, a feature that con-
firms earlier observations (Capilla et al., 2004).
Compared to other Enterobacteriaceae, small numbers of
Y. enterocolitica resistant to nalidixic acid have been reported
to date (Sa´nchez-Ce´spedes et al., 2003; Capilla et al., 2004;
Fa`brega et al., 2010; Sihvonen et al., 2011; Fredriksson-Ahomaa
et al., 2012). Although target gene mutations in gyrA are the
primary mechanism of resistance to nalidixic acid, efflux
pump activity, also contributes to support this phenotype.
This finding supports data reported earlier (Capilla et al.,
2004). Importantly, all three clinical isolates remain suscepti-
ble to ciprofloxacin.
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